Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)
ConditionHIV Disease Progression
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorPopulation Health Research Institute
About this trial
A double blinded, placebo-controlled, multicenter trial to evaluate effectiveness of azithromycin prophylaxis on mortality in advanced HIV.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Documented HIV infection
Ability to initiate or re-initiate ART, or switch to an effective ART regimen if failing current therapy, within 4 weeks of enrolment
Disqualifiers
Severe illness requiring immediate or continued hospitalization (this will be in the judgment of site investigators)
Off-label azithromycin prophylaxis or requirement for prolonged (> 7 days) azithromycin (or macrolide) therapy
Trial design
Treatments tested in this trial
- Azithromycin Oral Tablet
- Placebo oral tablet
Treatment groups
8,000 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov